ARA 290

ARA 290 is presented here as a laboratory catalogue entry for research environments that need clear identification, labelled variants, and direct access to supporting records. The current listing includes 1 labelled variant: 10mg. That structure keeps the page useful as both a procurement reference and an indexable resource covering stock visibility, pricing context, and documentation.

Within the wider Au Peptide Labs catalogue, ARA 290 sits alongside Retatrutide, Tesamorelin, and Ipamorelin. Researchers often review neighbouring compounds before selecting a comparator or deciding which sequence belongs in a screening panel. Keeping those internal paths close to the product page improves traceability and helps laboratory buyers compare materials without relying on vague or consumer-style copy.

In research literature, ARA 290 is generally treated as a non-hematopoietic cyclic peptide (11 residues) derived from the helix B surface of erythropoietin (EPO) that selectively engages the innate repair receptor (IRR) — a heterodimer of the β-common receptor (βcR) and the EPO receptor (EPOR). ARA 290 reproduces the tissue-protective signalling of erythropoietin without binding the homodimeric EPOR complex responsible for haematopoiesis, enabling research into EPO's non-erythropoietic functions. The β-common receptor (CD131)/EPOR heterodimer (IRR) activates PI3K/Akt and MAPK signalling pathways upon ARA 290 binding, producing anti-inflammatory, anti-apoptotic, and neuro-protective readouts in relevant cell models. Because it does not engage the canonical EPOR homodimer, it can be used in haematopoietic models without confounding red cell lineage effects.

ARA 290 is particularly valuable in experiments designed to separate EPO's tissue-protective functions from its erythropoietic actions. Research designs typically include full EPO, ARA 290, and IRR-selective antagonists as comparative conditions to attribute specific readouts to each receptor complex. For laboratory teams, the practical emphasis is usually on sequence identity, receptor or pathway relevance where documented, and whether ARA 290 behaves consistently across stability, purity, and analytical verification workflows. Variant labels on this page support clearer internal referencing when multiple labelled variants are under review.

If a product-specific file is not attached to this listing, the wider COA library remains the correct reference point for current published documentation. The COA section is useful for confirming how the product is labelled in the catalogue, whether purity information has been published, and whether the laboratory record for the material is complete before bench use.

When teams compare ARA 290 with Retatrutide, Tesamorelin, and Ipamorelin, COA access also helps keep comparator decisions grounded in documented material identity rather than assumption. That is especially important for research pages that combine pricing, variant selection, and analytical records on a single URL.